Business
Cardio Diagnostics Holdings Inc Sponsors Becker’s Hospital Review 11th Annual Meeting - The CEO + CFO Roundtable
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 11th Annual Meeting,
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 11th Annual Meeting, “The CEO + CFO Roundtable.” The conference is taking place this week, November 7-10, 2022, at the Hyatt Regency Hotel in Chicago. As part of Cardio Diagnostics’ sponsorship, Meesha Dogan, CEO, is sharing insights on the role of epigenetics in combating and altering the trajectory of heart disease at booth #120.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221108005658/en/Meesha Dogan, Ph.D. is the CEO, Co-Founder, Co-Inventor of the Integrated Epigenetic-Genetic Engine, and Board Member of Cardio Diagnostics. (Photo: Business Wire)\nBecker’s Hospital Review conferences are among the healthcare industry’s leading events covering hospital leaders' business, operational and patient-centered concerns. This annual meeting brings together more than 1000 CEOs and CFOs from across the country to discuss critical hospital leadership and management issues.\n\nCardio’s mission is to help physicians better detect and treat cardiovascular disease, the leading cause of death in the United States. At the core of its cardiovascular solutions is a proprietary Integrated Genetic-Epigenetic Engine™ created at the University of Iowa by company founders Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D. This technology enables the development of a series of tests for precision prevention and early detection and assists in the personalized treatment of major types of cardiovascular diseases and associated co-morbidities.\n\n\"We are pleased to sponsor Becker's Hospital Review 10th Annual Meeting and participate in this important event for healthcare leaders,\" said Dogan. \"This is a great opportunity to share Cardio’s insights on how we are partnering with leading healthcare organizations to drive risk stratification and population health initiatives that can bend the curve in heart disease, help lower costs and improve patient care.\"\n\nAbout Cardio Diagnostics\n\nCardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven ...